$2.02
-0.02 (-0.98%)
Open$2.02
Previous Close$2.04
Day High$2.04
Day Low$2.01
52W High$3.95
52W Low$1.56
Volume—
Avg Volume24.1K
Market Cap83.24M
P/E Ratio—
EPS$-0.66
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,577.7% upside
Current
$2.02
$2.02
Target
$33.89
$33.89
$29.33
$33.89 avg
$54.04
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 69.4K | 103.6K | 14.53M |
| Net Income | -27,334,011 | -36,750,238 | -1,603,701 |
| Profit Margin | -39,417.3% | -37,446.4% | -11.0% |
| EBITDA | -30,447,290 | -43,210,226 | -1,702,906 |
| Free Cash Flow | — | — | -884,905 |
| Rev Growth | -33.1% | -33.1% | +22.5% |
| Debt/Equity | — | — | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |